Xylocain Stungulyf, lausn 20 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

xylocain stungulyf, lausn 20 mg/ml

aspen pharma trading limited - lidocainum hýdróklóríð - stungulyf, lausn - 20 mg/ml

Xylocain adrenalin Stungulyf, lausn 10 mg/ml+5 míkróg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

xylocain adrenalin stungulyf, lausn 10 mg/ml+5 míkróg/ml

aspen pharma trading limited - lidocainum hýdróklóríð; adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 10 mg/ml+5 míkróg/ml

Ocaliva Evrópusambandið - íslenska - EMA (European Medicines Agency)

ocaliva

advanz pharma limited - obeticholic sýru - lifrarskroppur, galli - galla og lifrarmeðferð - ocaliva er ætlað fyrir meðferð aðal galli cholangitis (einnig þekktur sem aðal galli skorpulifur) ásamt úrsódeoxýkólsýru (udca) í fullorðnir með ófullnægjandi að bregðast við udca eða eitt og sér í fullorðnir ekki að þola udca.

Pelmeg Evrópusambandið - íslenska - EMA (European Medicines Agency)

pelmeg

mundipharma corporation (ireland) limited - pegfilgrastim - daufkyrningafæð - Ónæmisörvandi, - til að draga úr lengd mæði í tengslum og tíðni hita og mæði í tengslum vegna lyfjameðferð.

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Evrópusambandið - íslenska - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - blóðþurrðandi lyf - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). l hækkun, bráð myndun stíflufleygs, ásamt asa í læknisfræðilega sjúklingum rétt fyrir segaleysandi meðferð. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. nánari upplýsingar er að vísa til kafla 5.

Betadine Baðlyf 75 mg/g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

betadine baðlyf 75 mg/g

mundipharma a/s - povidonum iodinatum inn - baðlyf - 75 mg/g

Betadine Húðlausn 100 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

betadine húðlausn 100 mg/ml

mundipharma a/s - povidone, iodinated - húðlausn - 100 mg/ml

Betadine Húðlausn 100. mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

betadine húðlausn 100. mg/ml

mundipharma a/s - povidone, iodinated - húðlausn - 100. mg/ml

Betadine Húðvökvi 100 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

betadine húðvökvi 100 mg/ml

mundipharma a/s - povidone, iodinated - húðvökvi - 100 mg/ml

Clariscan Stungulyf, lausn 0,5 mmól/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

clariscan stungulyf, lausn 0,5 mmól/ml

ge healthcare as - acidum gadotericum inn - stungulyf, lausn - 0,5 mmól/ml